Clarification concerning Impact of the COVID-19 Pandemic

Response ID	
2079	

Profile

Ticker/Listed Company Name

WEGE - PT Wijaya Karya Bangunan Gedung Tbk. [A730]

Section 1

In order to obtain the latest information on the Company's operating conditions and financial performance, the Exchange finds it necessary to raise queries on the following matters:

What is the Company's current business continuity status?

a. Affected by COVID-19 [A1]

Does the COVID-19 Pandemic cause a **suspension and/or restriction** in the Company and/or Subsidiaries' operations?

Yes. It causes restricted operations only [c]

What is the estimated duration of the operating suspension/restriction?

More than 3 months [c]

Please describe further the type of activities that are affected by suspension and/or restriction of the Company and/or Subsidiaries' operations (for example: business segment suspended; business unit suspended; business location suspended; etc.)

Example: Company A suspended packing operations located in City X

The Company restricted operations at the Head Office by adopting Work from Home (WFH) from March 2020. On-site project activities proceed normally by observing COVID-19 protocols.

What is the **revenue contribution** of the suspended and/or restricted operating activities to the total revenue (consolidated) for 2019?

Less than 25% [a]

In relation to employees affected by the COVID-19 Pandemic, please describe:

a. Total employees (permanent and non-permanent)

[As at 31 December 2019] [Total employees (permanent and non-permanent)]

775

In relation to employees affected by the COVID-19 Pandemic, please describe:

a. Total employees (permanent and non-permanent)

[Present] [Total employees (permanent and non-permanent)]

794

[Total employees terminated] [Employees from January 2020 to present]

0

[Total employees furloughed] [Employees from January 2020 to present]

0

[Total employees affected by other status (for example: 50% pay deduction, etc.)] [Employees from January 2020 to present]

0

What is the estimated reduction in total revenue (consolidated) for the period ended on 31 March 2020³/30 April 2020⁵ (pro forma figures may be used) compared with the period ended on 31 March 2019³/30 April 2019⁵

- ^a For Listed Companies where the financial year ends on 31 December, 31 March, or 30 June
- ^b For Listed Companies where the financial year ends on 31 January

Less than 25% [a]

What is the estimated impact to profit/loss for the period ended on 31 March 2020^a/30 April 2020^b (pro forma figures may be used) compared with the period ended on 31 March 2019^a/30 April 2019^b

- ^a For Listed Companies where the financial year ends on 31 December, 31 March, or 30 June
- ^b For Listed Companies where the financial year ends on 31 January

Profit increase will be less 25% [e]

Does the COVID-19 Pandemic affect the Company and/or Subsidiaries' most recent **short-term financial liabilities** (Trade Payables, Bank/Financial Institution Payables, Bond Coupon and/or Bond Principal, Medium-term Notes, etc.)?

No effects [d]

Does the COVID-19 Pandemic cause material **Legal Issues** to the Company and/or Subsidiaries, i.e. bankruptcy petition/suspension of debt repayment (*Penundaan Kewajiban Pembayaran Utang*, "**PKPU**")?

No [A2]

Does the COVID-19 Pandemic cause material **Legal Issues** to the Company and/or Subsidiaries, i.e. annulment of material contracts?

No [A2]

Does the COVID-19 Pandemic cause material **Legal Issues** to the Company and/or Subsidiaries, i.e. service of default notices (*somasi*) or legal claims due to default?

No [A2]

Does the COVID-19 Pandemic cause material **Legal Issues** to the Company and/or Subsidiaries other than the 3 (three) matters stated above?

No [A2]

What are the Company's strategies/measures to maintain its business continuity during the COVID-19 Pandemic?

The Company's strategies/measures to maintain its business continuity during the COVID-19 Pandemic are as follows:

- 1. Seeking opportunities to construct healthcare facilities, such as Designated COVID-19 Hospitals
- 2. Imposing cost efficiency measures at the Bureau and Division levels
- 3. Optimising CAPEX spending